Immunotherapy for Esophageal Cancer: A 2019 Update
- 1 February 2020
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 12 (3) , 203-218
Abstract
Esophageal cancer remains a global health concern with a dismal prognosis and an estimated 5-year survival rate of approximately 10–15%. Immunotherapy is a novel treatment approach representing an ...Keywords
This publication has 76 references indexed in Scilit:
- Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patientsJournal of Translational Medicine, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Clinicopathologic and Molecular Profiles of Microsatellite Unstable Barrett Esophagus-associated AdenocarcinomaAmerican Journal of Surgical Pathology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagusEuropean Journal of Surgical Oncology, 2010
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal AdenocarcinomaClinical Cancer Research, 2010
- Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingNature Reviews Immunology, 2007
- Identification of human leukocyte antigen‐A24‐restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapyCancer Science, 2007
- Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or PleuraClinical Cancer Research, 2006
- An open‐label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5‐fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer : The GC4 studyCancer, 2006